Christopher Christie
CIK 1787688 · View on SEC EDGAR ↗
Insider
First SEC filing: Sept. 20, 2019 · Latest: June 12, 2026
On this page
Insider at
Insider transactions
0 buys (P)
0 sells (S)
Net:
$0
+ 15 non-open-market transactions below
last 12 months, based on the transactions shown below
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
No open-market trades on record; showing all filings.
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| June 10, 2026 | PCRX | A | 10,891 | — | — | 10,891 Direct | — | Acquired | (price as of 2026-08-20) |
| June 10, 2026 | PCRX | A | 6,405 | — | — | 23,059 Direct | +38.46% | Acquired | (price as of 2026-08-20) |
| June 11, 2025 | PCRX | A | 6,163 | — | — | 16,654 Direct | +58.75% | Acquired | (price as of 2026-08-20) |
| June 11, 2025 | PCRX | A | 11,279 | — | — | 11,279 Direct | — | Acquired | (price as of 2026-08-20) |
| June 12, 2024 | PCRX | A | 5,230 | — | — | 10,491 Direct | +99.41% | Acquired | (price as of 2026-08-20) |
| June 12, 2024 | PCRX | A | 12,179 | — | — | 12,179 Direct | — | Acquired | (price as of 2026-08-20) |
| June 14, 2023 | PCRX | A | 12,925 | — | — | 12,925 Direct | — | Acquired | (price as of 2026-08-20) |
| June 14, 2023 | PCRX | A | 1,775 | — | — | 5,261 Direct | +50.92% | Acquired | (price as of 2026-08-20) |
| June 8, 2022 | PCRX | A | 8,225 | — | — | 8,225 Direct | — | Acquired | (price as of 2026-08-20) |
| June 8, 2022 | PCRX | A | 1,160 | — | — | 3,486 Direct | +49.87% | Acquired | (price as of 2026-08-20) |
| June 9, 2021 | PCRX | A | 1,066 | — | — | 2,326 Direct | +84.60% | Acquired | (price as of 2026-08-20) |
| June 9, 2021 | PCRX | A | 7,626 | — | — | 7,626 Direct | — | Acquired | (price as of 2026-08-20) |
| June 9, 2020 | PCRX | A | 8,027 | — | — | 8,027 Direct | — | Acquired | (price as of 2026-08-20) |
| June 9, 2020 | PCRX | A | 1,260 | — | — | 1,260 Direct | — | Acquired | (price as of 2026-08-20) |
| Sept. 18, 2019 | PCRX | A | 19,919 | — | — | 19,919 Direct | — | Acquired | (price as of 2026-08-20) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| June 10, 2026 | PCRX | Stock Option (Right to Buy) | Common Stock (10,891) | $23.42 | June 10, 2036 | 10,891 | Acquired |
| June 11, 2025 | PCRX | Stock Option (Right to Buy) | Common Stock (11,279) | $24.34 | June 11, 2035 | 11,279 | Acquired |
| June 12, 2024 | PCRX | Stock Option (Right to Buy) | Common Stock (12,179) | $28.68 | June 12, 2034 | 12,179 | Acquired |
| June 14, 2023 | PCRX | Stock Option (Right to Buy) | Common Stock (12,925) | $38.74 | June 14, 2033 | 12,925 | Acquired |
| June 8, 2022 | PCRX | Stock Option (Right to Buy) | Common Stock (8,225) | $59.39 | June 8, 2032 | 8,225 | Acquired |
| June 9, 2021 | PCRX | Stock Option (Right to Buy) | Common Stock (7,626) | $60.96 | June 9, 2031 | 7,626 | Acquired |
| June 9, 2020 | PCRX | Stock Option (Right to Buy) | Common Stock (8,027) | $47.65 | June 9, 2030 | 8,027 | Acquired |
| Sept. 18, 2019 | PCRX | Stock Option (Right to Buy) | Common Stock (19,919) | $37.16 | Sept. 18, 2029 | 19,919 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 2 holdings
Securities held when first becoming an insider, per SEC Form 3.